Bio Green Med Solution Inc

BGMS

Market cap $4.03M

Bio Green Med Solution, Inc. (NASDAQ:BGMS) shares are trading higher Friday after the company announced it entered into a Business Combination Agreement with Future NRG.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Bio Green Med Solution, Inc. (NASDAQ: BGMS) and Future NRG Sdn. Bhd. Halper Sadeh encourages BGMS shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether BGMS and its board of directors violated the federal securiti.

KUALA LUMPUR, MALAYSIA, June 04, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; the “Company”) today announced that it entered into a Business Combination Agreement (“BCA”) with Future NRG Sdn. Bhd. (“Future NRG”) in an all stock share exchange transaction. Future NRG is a Malaysia-based technology integrator and project developer operating at the forefront of innovative and sustainable medical waste management, for healthcare waste generators including clinics, dental practices, veterinary clinics, dialysis centers, laboratories, and factories, offering advanced waste-to-energy and waste-to-resource projects using advanced, market-proven clean technology. Upon completion of the share exchange, which is subject to approval by BGMS and Future NRG's shareholders, the combined company is expected to continue operating under the name Bio Green Med Solution, Inc. and continue trading on the Nasdaq Capital Market under the ticker symbol “BGMS”.

KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced first quarter financial results and provided a business update.

KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced fourth quarter and full year 2025 financial results and provided a business update.

KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced third quarter financial results and provided a business update.

KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update.

- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, “ Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ” in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells.

Cyclacel Pharmaceuticals, Inc. CYCC stock is trading higher on Tuesday, with a session volume of 21.9 million compared to the average volume of 206.9K, as per data from Benzinga Pro.

- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and          occurs mostly in adolescents and young adults -